0001193125-26-207530
SEC filingFibroBiologics increased its at-the-market offering capacity to $7,500,000 via prospectus supplement and filed counsel opinion validating shares sold through H.C. Wainwright.
FibroBiologics entered into an At The Market Offering Agreement on May 1, 2026 with H.C. Wainwright & Co., LLC, enabling flexible sales of common stock without fixed pricing or volume commitments. The May 5, 2026 prospectus supplement expanded the offering's capacity to $7.5 million aggregate value, building on the effective S-3 shelf registration from February 2025. To date, modest sales of 71,830 shares indicate early utilization. The filed legal opinion from Sichenzia Ross Ference Carmel LLP validates the shares' authorization and nonassessable status under Delaware and New York law, supporting ongoing issuances. This structure provides the company liquidity for operations while minimizing immediate dilution impact, with investor access through the sales agent.